APCMA

PCMA Member Survey:
The ImpaCt of POS Rebates and POS Pharmacy DIR

The Pharmaceutical Care Management Association (PCMA) had an independent third
party conduct a survey of its members to assess the potential impact on 
premiums for Medicare Prescription Drug Plans (PDPs) if all drug manufacturer rebates
and pharmacy direct and indirect remuneration (DIR) were required to be applied at the
point of sale (POS) starting next year.

Six PCMA member companies with more than 14.6 million PDP enrollees in 2018
responded to the survey, which was conducted in January 2018.

Below are the aggregate average results for these companies reported to PCMA on an
enrollment-weighted basis:

. Medicare PDPs expect that 100% of PDP plans and virtually all PDP enrollees
would be impacted if manufacturer rebates and pharmacy DIR were required to
be applied at the point of sale (POS).

- premiums for Medicare PDPs would rise by an expected 22% in 2019 if
all manufacturer rebates and all pharmacy DIR were required to be applied at
P08.

Requiring all manufacturer rebates be applied at P08 would increase
premiums 17%.

Requiring all pharmacy DIR be applied at P08 would increase 
premiums by